Tags : Multiple Sclerosis

Novartis and Siemens Collaborate to Develop Blood Tests for Multiple

Shots: The companies enter in a master agreement to design, develop, and commercialize diagnostic tests for therapies Novartis’ therapeutic pipeline The collaboration will initially focus on the development of serum neurofilament light chain (NfL) immunoassay for patients with MS and other neurological diseases Siemens will leverage its expertise in the development of clinical diagnostic solutions […]Read More

Roche to Present New Data of Ocrevus (ocrelizumab) for Relapsing-Remitting

Shots: Roche divulges new data that demonstrate Ocrevus (ocrelizumab) is a highly effective treatment option for people with RRMS who experienced a suboptimal response to their prior DMT. In open-label P-IIIb CASTING study, 75% of patients with RRMS and suboptimal response to prior treatment had no evidence of disease activity 2yrs. after switching to Ocrevus […]Read More

Immunic Reports Results of IMU-838 in P-II EMPhASIS Study in

Shots: The P-II EMPhASIS study involves assessing of IMU-838 in 210 patients randomized in 36 centers across 4 EU countries, 209 patients received at least one dose of IMU-838 vs PBO and 197 patients completed @24-wks. treatment period The study resulted in meeting its 1EPs & 2EPs: 62% & 70% reduction in CUA MRI lesions […]Read More

Roche Signs RWD Collaboration with PicnicHealth to Create Personalized Treatment

Shots: The real-world evidence partnership will allow the Roche to access PicnicHealth’s set of de-identified patient records to gain insights on certain diseases and treatments The collaboration will initially focus on MS and may be extended to support Huntington’s disease (HD), paroxysmal nocturnal hemoglobinuria (PNH), and hemophilia The companies signed a multi-year collaboration that combines […]Read More

BMS Signs an Exclusive Option to License Agreement with Dragonfly

Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide IPR for multiple candidates developed using Dragonfly’s platform for multiple new targets The focus of the agreement is to expand the collaboration b/w the companies […]Read More

BMS’ Zeposia (ozanimod) Receives the US FDA’s Approval as New

Shots: The approval is based on P-III SUNBEAM & RADIANCE Part B studies assessing Zeposia (0.92 mg, equivalent to 1mg) vs Avonex (interferon beta-1a, qw, IM) in 1,346 & 1,320 patients with RMS for at least 12 & 24mos. treatment period respectively Collective results: @1yr. & @2yrs.; reduction in ARR of 48% & 38% (0.18 […]Read More

Janssen Reports Submission of Ponesimod’s NDA to the US FDA

Shots: The NDA is based on P-III OPTIMUM study assessing ponesimod (20mg) vs Aubagio (teriflunomide, 14 mg) in patients with relapsing MS The P-III OPTIMUM study results: reduction in ARR (30.5%); reduction in CUALs (56%); reduction in fatigue symptoms; safety profile is consistent with the previous studies Ponesimod is an investigational S1P1 modulator, act by […]Read More